Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-Caffeoyltyramine is a naturally occurring small molecule classified as a hydroxycinnamic acid amide, specifically a phenylpropanoid amide. It consists of a caffeoyl group attached to a tyramine backbone and is found in various plants, including Lycium chinense (goji berry) and Solanum tuberosum (potato). N-Caffeoyltyramine exhibits notable antioxidant, anti-inflammatory, and arginase inhibitory properties. Mechanistically, it inhibits the production of nitric oxide (NO), tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-6), interleukin 10 (IL-10), cyclooxygenase 2 (COX-2), and prostaglandin E2 in LPS-stimulated macrophages. It also suppresses c-Jun N-terminal kinase phosphorylation. Additional studies indicate that it can inhibit epidermal growth factor receptor protein tyrosine kinase activity and activate caspase 3, suggesting potential anti-cancer effects. More recently, N-Caffeoyltyramine has been identified as an agonist of hepatocyte nuclear factor 4 alpha (HNF4α) with implications for metabolic diseases such as non-alcoholic fatty liver disease by promoting mitochondrial function and lipophagy[1][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on n-caffeoyltyramine.